Screener
Rigel Pharmaceuticals RIGL Income Tax
Income Tax at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest income | 1,205 | 591 |
| Interest expense | (1,433) | (1,853) |
| Income before income taxes | 11,657 | 11,511 |
| Provision for income taxes | 3,003 | 65 |
| Net income | $8,654 | $11,446 |
| Net income per share | ||
| Basic | $0.47 | $0.64 |
| Diluted | $0.44 | $0.63 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's income tax?
- Rigel Pharmaceuticals (RIGL) reported income tax of $3M in Q1 2026.
- How has Rigel Pharmaceuticals's income tax changed year-over-year?
- Rigel Pharmaceuticals's income tax increased by 4520.0% year-over-year, from $65K to $3M.
- What is the long-term trend for Rigel Pharmaceuticals's income tax?
- Over 3 years (2021 to 2025), Rigel Pharmaceuticals's income tax has grown at a 617.1% compound annual growth rate (CAGR), from $665K to -$245.2M.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about Rigel Pharmaceuticals's income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude